Clinical trial
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally…
NCT00085371 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085371 |
|---|---|
| Title | Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas |
| Official title | A Phase II Study Of Triapine For Advanced Adenocarcinoma Of The Pancreas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | triapine |
| Enrollment | 116 |
| Start date | Jul 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | Jun 11, 2004 |
| Last update posted | Oct 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: